Definitions and mechanisms of the metabolic syndrome

Current Opinion in Endocrinology and Diabetes

Volumn 13, Issue 2, 2006, Pages 103-110

  Meigs, James B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cardiovascular disease; Epidemiology; Insulin resistance; Metabolic syndrome; Obesity; Prevention; Risk factors; Type 2 diabetes

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADIPOCYTE; ADULT TREATMENT PANEL 3; ADVISORY COMMITTEE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; HEALTH PROGRAM; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; META ANALYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHENOTYPE; PREDICTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

EID: 33646065692     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000216957.13633.58     Document Type: Review

References (50)

1. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102:42-47.
2. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283:221-228.
3. Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors of the insulin resistance syndrome. Am J Epidemiol 2000; 152:897-907.
4. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
5. Haffner SM, Valdez RA, Hazuda HP, et al. Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 1992; 41:715-722.
6. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752. This is the most current statement of the rationale, definition, and intended use of the ATP3 metabolic syndrome. Although the ATP3 definition will remain controversial, this document is a fundamental 'must read' element of the metabolic syndrome literature.
7. Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366:1059-1062.
8. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 199; 16:442-443.
9. World Health Organization. WHO Expert Committee on Diabetes Mellitus: second report. Geneva: World Health Organization; 1980.
10. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9:237-252.
11. Alexander CM. The coming of age of the metabolic syndrome. Diabetes Care 2003; 26:3180-3181.
12. Vinicor F, Bowman B. The metabolic syndrome: the emperor needs some consistent clothes. Diabetes Care 2004; 27:1243; author reply 1244.
13. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28:2289-2304. This article is the key paper questioning the widely accepted value of the metabolic syndrome. The paper very helpfully identifies key areas of needed research.
14. Gale EA. The myth of the metabolic syndrome. Diabetologia 2005; 48:1679-1683. Perhaps the most thoughtful and entertaining critique yet published of the metabolic syndrome and the surrounding debate.
15. Ford ES. Rarer than a blue moon: the use of a diagnostic code for the metabolic syndrome in the U.S. Diabetes Care 2005; 28:1808-1809.
16. Yarnell JW, Patterson CC, Bainton D, Sweetnam PM. Is metabolic syndrome a discrete entity in the general population? Evidence from the Caerphilly and Speedwell population studies. Heart 1998; 79:248-252.
17. Schmidt MI, Watson RL, Duncan BB, et al. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Metabolism 1996; 45:699-706.
18. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders. Diabetes 1998; 47:1643-1649.
19. Wilson PWF, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159:1104-1109.
20. Liese AD, Mayer-Davis EJ, Tyroler HA, et al. Development of the multiple metabolic syndrome in the ARIC cohort: joint contribution of insulin, BMI, and WHR. Atherosclerosis risk in communities. Ann Epidemiol 1997; 7:407-416.
21. Wei M, Gaskill SP, Haffner SM, Stern MP. Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans: a 7-year prospective study. Obesity Res 1997; 5:16-23.
22. Palaniappan L, Carnethon MR, Wang Y, et al. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004; 27:788-793.
23. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53:2087-2094.
24. Meigs JB. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000; 152:908-911.
25. Wilson PWF, D'Agostino RB Sr, Parise H, et al. The metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112:3066-3072. This study offers the most comprehensive, community-based evaluation of metabolic syndrome as a risk factor for type 2 diabetes and CVD yet published.
26. Cheal KL, Abbasi F, Lamendola C, et al. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004; 53:1195-1200.
27. Liao Y, Kwon S, Shaughnessy S, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004; 27:978-983.
28. Bonora E, Targher G, Formentini G, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004; 21:52-58.
29. Bruno G, Merletti F, Biggeri A, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004; 27:2689-2694.
30. Stern MP, Williams K, Gonzalez-Villalpando C, et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27:2676-2681.
31. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-438.
32. Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004; 27:1182-1186.
33. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
34. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28:1769-1778.
35. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the 'metabolic syndrome' and incidence of type 2 diabetes. Diabetes 2002; 51:3120-3127.
36. Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164:1066-1076.
37. Rutter MK, Meigs JB, Sullivan LM, et al. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in The Framingham Offspring Study. Diabetes 2005; 54:3252-3257.
38. Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112:666-673.
39. Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004; 159:882-890.
40. Bonora E, Kiechl S, Willeit J, et al. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord 2003; 27:1283-1289.
41. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107:391-397.
42. Rutter MK, Meigs JB, Sullivan LM, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110:380-385.
43. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46:459-469.
44. Tschritter O, Fritsche A, Thamer C, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52:239-243.
45. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361:226-228.
46. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360:57-58.
47. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin J. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997; 46 (Suppl 2):S9-S13.
48. Caballero AE, Arora S, Saouaf R, Lim SC, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48:1856-1862.
49. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291:1978-1986.
50. Meigs JB, Wilson PWF. Tofler GH, et al. Markers of endothelial dysfunction predict incident type 2 diabetes [abstract]. Diabetes 2005; 54 (Suppl 1):A90.